Literature DB >> 22586569

Targeting NF-κB in mouse models of lung adenocarcinoma.

Carter Van Waes1.   

Abstract

Xue et al. demonstrate response and increased survival but development of acquired resistance to proteasome and inhibitor-κB kinase inhibitors targeting NF-κB activation in adenocarcinomas of Kras-activated, p53-deficient mice.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22586569      PMCID： PMC3526371          DOI： 10.1158/2159-8290.CD-11-0159

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  9 in total

1.  ΔNp63 versatilely regulates a Broad NF-κB gene program and promotes squamous epithelial proliferation, migration, and inflammation.

Authors:  Xinping Yang; Hai Lu; Bin Yan; Rose-Anne Romano; Yansong Bian; Jay Friedman; Praveen Duggal; Clint Allen; Ryan Chuang; Reza Ehsanian; Han Si; Satrajit Sinha; Carter Van Waes; Zhong Chen
Journal:  Cancer Res       Date:  2011-05-15       Impact factor: 12.701

2.  Genetically informed lung cancer medicine.

Authors:  William Pao; A John Iafrate; Zengliu Su
Journal:  J Pathol       Date:  2010-10-25       Impact factor: 7.996

Review 3.  Nuclear factor-kappaB in development, prevention, and therapy of cancer.

Authors:  Carter Van Waes
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

4.  Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

Authors:  Michael P Fanucchi; Frank V Fossella; Robert Belt; Ronald Natale; Panos Fidias; David P Carbone; Ramaswamy Govindan; Luis E Raez; Francisco Robert; Maria Ribeiro; Wallace Akerley; Karen Kelly; Steven A Limentani; Jeffrey Crawford; Hans-Joachim Reimers; Rita Axelrod; Oscar Kashala; Shihong Sheng; Joan H Schiller
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

5.  Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.

Authors:  Changyou Li; Yan Zang; Malabika Sen; Rebecca J Leeman-Neill; David S K Man; Jennifer R Grandis; Daniel E Johnson
Journal:  Mol Cancer Ther       Date:  2009-07-28       Impact factor: 6.261

6.  Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.

Authors:  Clint Allen; Kunal Saigal; Liesl Nottingham; Pattatheyil Arun; Zhong Chen; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

7.  Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.

Authors:  Zhong Chen; Justin L Ricker; Pramit S Malhotra; Liesl Nottingham; Lorena Bagain; Tin Lap Lee; Ning T Yeh; Carter Van Waes
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

8.  Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.

Authors:  Wen Xue; Etienne Meylan; Trudy G Oliver; David M Feldser; Monte M Winslow; Roderick Bronson; Tyler Jacks
Journal:  Cancer Discov       Date:  2011-06-16       Impact factor: 39.397

9.  Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma.

Authors:  Etienne Meylan; Alison L Dooley; David M Feldser; Lynn Shen; Erin Turk; Chensi Ouyang; Tyler Jacks
Journal:  Nature       Date:  2009-10-21       Impact factor: 49.962
  9 in total
  3 in total

1.  Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.

Authors:  Jipei Liao; Zejia Yang; Brandon Carter-Cooper; Elizabeth T Chang; Eun Yong Choi; Bhaskar Kallakury; Xuefeng Liu; Rena G Lapidus; Kevin J Cullen; Hancai Dan
Journal:  Clin Exp Metastasis       Date:  2020-02-04       Impact factor: 5.150

2.  CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer.

Authors:  Clint T Allen; Barbara Conley; John B Sunwoo; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2015-03-01       Impact factor: 12.531

3.  IκB Kinase α Is Required for Development and Progression of KRAS-Mutant Lung Adenocarcinoma.

Authors:  Malamati Vreka; Ioannis Lilis; Maria Papageorgopoulou; Georgia A Giotopoulou; Marina Lianou; Ioanna Giopanou; Nikolaos I Kanellakis; Magda Spella; Theodora Agalioti; Vasileios Armenis; Torsten Goldmann; Sebastian Marwitz; Fiona E Yull; Timothy S Blackwell; Manolis Pasparakis; Antonia Marazioti; Georgios T Stathopoulos
Journal:  Cancer Res       Date:  2018-03-27       Impact factor: 12.701
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.